Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free su...

Descripción completa

Detalles Bibliográficos
Autores principales: Javle, M, Yu, J, Garrett, C, Pande, A, Kuvshinoff, B, Litwin, A, Phelan, J, Gibbs, J, Iyer, R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/
https://www.ncbi.nlm.nih.gov/pubmed/19491904
http://dx.doi.org/10.1038/sj.bjc.6605099
_version_ 1782169654271148032
author Javle, M
Yu, J
Garrett, C
Pande, A
Kuvshinoff, B
Litwin, A
Phelan, J
Gibbs, J
Iyer, R
author_facet Javle, M
Yu, J
Garrett, C
Pande, A
Kuvshinoff, B
Litwin, A
Phelan, J
Gibbs, J
Iyer, R
author_sort Javle, M
collection PubMed
description A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%).
format Text
id pubmed-2714236
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27142362010-06-16 Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study Javle, M Yu, J Garrett, C Pande, A Kuvshinoff, B Litwin, A Phelan, J Gibbs, J Iyer, R Br J Cancer Short Communication A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg(−1), capecitabine 1300 mg m(−2) daily for 2 weeks and gemcitabine 1000 mg m(−2) weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%). Nature Publishing Group 2009-06-16 2009-06-02 /pmc/articles/PMC2714236/ /pubmed/19491904 http://dx.doi.org/10.1038/sj.bjc.6605099 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Javle, M
Yu, J
Garrett, C
Pande, A
Kuvshinoff, B
Litwin, A
Phelan, J
Gibbs, J
Iyer, R
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title_full Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title_fullStr Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title_full_unstemmed Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title_short Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
title_sort bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase ii study
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714236/
https://www.ncbi.nlm.nih.gov/pubmed/19491904
http://dx.doi.org/10.1038/sj.bjc.6605099
work_keys_str_mv AT javlem bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT yuj bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT garrettc bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT pandea bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT kuvshinoffb bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT litwina bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT phelanj bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT gibbsj bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy
AT iyerr bevacizumabcombinedwithgemcitabineandcapecitabineforadvancedpancreaticcanceraphaseiistudy

Ejemplares similares